A new porphyrin as selective substrate-based inhibitor of breast cancer resistance protein (BCRP/ABCG2).

Autor: Zattoni IF; Pharmaceutical Sciences Graduate Program, Laboratory of Cancer Drug Resistance, Federal University of Parana, Curitiba, PR, Brazil., Kronenberger T; School of Pharmacy, University of Eastern Finland, Faculty of Health Sciences, Kuopio, 70211, Finland; Department of Medical Oncology and Pneumology, Internal Medicine VIII, University Hospital of Tübingen, Otfried-Müller-Strasse 14, 72076, Tübingen, Germany., Kita DH; Pharmaceutical Sciences Graduate Program, Laboratory of Cancer Drug Resistance, Federal University of Parana, Curitiba, PR, Brazil; Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Guanaes LD; Department of Pharmacy, Federal University of Parana, Curitiba, PR, Brazil., Guimarães MM; Department of Pharmacy, Federal University of Parana, Curitiba, PR, Brazil., de Oliveira Prado L; Department of Clinical Analysis, Federal University of Parana, Curitiba, PR, Brazil., Ziasch M; Department of Clinical Analysis, Federal University of Parana, Curitiba, PR, Brazil., Vesga LC; School of Pharmacy, University of Eastern Finland, Faculty of Health Sciences, Kuopio, 70211, Finland; Research Group in Biochemistry and Microbiology (GIBIM), School of Chemistry, Industrial University of Santander, A.A. 678, Bucaramanga, Colombia; Research Group on Organic Compounds of Medicinal Interest (CODEIM), Technological Park of Guatiguara, Industrial University of Santander, A. A. 678, Piedecuesta, Colombia., Gomes de Moraes Rego F; Department of Clinical Analysis, Federal University of Parana, Curitiba, PR, Brazil., Picheth G; Department of Clinical Analysis, Federal University of Parana, Curitiba, PR, Brazil., Gonçalves MB; Department of Physics, Federal Technological University of Paraná, 80230-901 Curitiba, Parana, Brazil., Noseda MD; Department of Biochemistry and Molecular Biology, Federal University of Paraná, Curitiba, Paraná, Brazil., Ducatti DRB; Department of Biochemistry and Molecular Biology, Federal University of Paraná, Curitiba, Paraná, Brazil., Poso A; School of Pharmacy, University of Eastern Finland, Faculty of Health Sciences, Kuopio, 70211, Finland; Department of Medical Oncology and Pneumology, Internal Medicine VIII, University Hospital of Tübingen, Otfried-Müller-Strasse 14, 72076, Tübingen, Germany., Robey RW; Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Ambudkar SV; Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Moure VR; Pharmaceutical Sciences Graduate Program, Laboratory of Cancer Drug Resistance, Federal University of Parana, Curitiba, PR, Brazil; Department of Clinical Analysis, Federal University of Parana, Curitiba, PR, Brazil., Gonçalves AG; Department of Pharmacy, Federal University of Parana, Curitiba, PR, Brazil. Electronic address: alan.goncalves@ufpr.br., Valdameri G; Pharmaceutical Sciences Graduate Program, Laboratory of Cancer Drug Resistance, Federal University of Parana, Curitiba, PR, Brazil; Department of Clinical Analysis, Federal University of Parana, Curitiba, PR, Brazil. Electronic address: gvaldameri@ufpr.br.

Publikováno v: Chemico-biological interactions [Chem Biol Interact] 2022 Jan 05; Vol. 351, pp. 109718. Date of Electronic Publication: 2021 Oct 27.